Form 4: Randal J. Kirk Reports Acquisition of Precigen Stock and Derivative Securities

Randal J. Kirk, a director and 10% owner of Precigen, Inc., reported the acquisition of common stock, restricted stock units, and options to purchase common stock.

Summary

• On March 14, 2024, Randal J. Kirk acquired 69,930 shares of Precigen, Inc. common stock at a price of $1.43 per share.
• Kirk also acquired 174,825 restricted stock units, each representing a contingent right to receive one share of Precigen common stock, vesting on the one-year anniversary of the grant date.
• Additionally, Kirk acquired an option to purchase 203,252 shares of common stock at a price of $1.43, exercisable from March 14, 2024, to March 14, 2034.
• Following these transactions, Kirk's total indirect beneficial ownership includes significant holdings through various entities, such as R.J. Kirk Declaration of Trust, Parkview 2020 Limited Partnership, and others.
• Kirk disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director and significant shareholder is increasing their stake in the company, which can be seen as a vote of confidence. However, it's important to note the disclaimer of beneficial ownership, which tempers the positive sentiment slightly.

Positives

• The acquisition of shares and derivative securities by a director and significant shareholder could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The restricted stock units vest on the one-year anniversary of the grant date, contingent upon continued service to the issuer.

Management Comments

• Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. A purchase by a director and significant shareholder is often viewed positively.

Comparison to Industry Standards

• Comparing this transaction to similar insider transactions in the biotechnology industry, it's common to see stock and option grants as part of executive compensation packages.
• Companies like Amgen and Gilead Sciences also use stock options and restricted stock units to align management's interests with shareholders.
• The size of the transaction is significant, indicating a substantial investment by Mr. Kirk in Precigen's future.

Stakeholder Impact

• Shareholders may view the insider purchase as a positive signal.
• Employees may see it as a sign of stability and confidence in the company's leadership.

Key Dates